Amarantus Bioscience Holdings Inc (AMBS)

[gulf shores man]

Spend 5 million now vs 500 million profit from LimPro annually no brainer here.
From Presidents letter to shareholder's:
It is estimated that the cost of caring for patients with dementia will exceed $200B in 2013; we believe the potential for LymPro exceeds $500M annually;
• The market for Parkinson's diseases drugs exceeded $3B worldwide in 2008; we believe the market potential for MANF in Parkinson's exceeds $1B annually;
• The market for the orphan indications currently being evaluated under our CEAR grant exceeds $1B; we believe the market potential for MANF in these orphan indications exceeds $1B annually;
• The markets for diabetes, ischemic heart disease and traumatic brain injury exceeds $100B annually; we believe the market potential for MANF in other indications exceeds $3B annually;